DOCSLIB.ORG

University of Würzburg Medical Faculty Research Report 2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Würzburg Medical Faculty Research Report 2008 University of Würzburg University of Würzburg Universitätsklinikum Würzburg Medical Faculty Medical Faculty Josef-Schneider-Str. 2 · 97080 Würzburg 2008 Report – Research University of Würzburg Medical Faculty http://www.uni-wuerzburg.de/ueber/fakultaeten/ Research Report 2008 medizin/startseite/ University of Würzburg Medical Faculty Research Report 2008 Content 1 General Part 1.1 Preface 1.2 Medical Education ...................................................................................................................................................... 6 1.3 Students’ Representatives ........................................................................................................................................... 9 1.4 The History of the Würzburg Medical Faculty ................................................................................................................ 10 2 Research Institutes 2.1 Institute of Anatomy and Cell Biology I ........................................................................................................................ 12 2.2 Institute of Anatomy and Cell Biology II ....................................................................................................................... 14 2.3 Institute of Physiology I ............................................................................................................................................ 16 2.4 Institute of Physiology II ............................................................................................................................................ 18 2.5 Biocenter Würzburg Chair of Physiological Chemistry I .................................................................................................. 20 2.6 Biocenter Würzburg Chair of Physiological Chemistry II ................................................................................................. 22 2.7 Institute for the History of Medicine ............................................................................................................................ 24 2.8 Institute of Psychotherapy and Medical Psychology ..................................................................................................... 26 2.9 Institute for Hygiene and Microbiology ....................................................................................................................... 28 2.10 Institute of Virology and Immunobiology, Chair of Virology ............................................................................................ 30 2.11 Institute of Virology and Immunobiology, Chair of Immunology ....................................................................................... 32 2.12 Institute for Molecular Infection Biology ...................................................................................................................... 34 2.13 Institute of Pharmacology and Toxicology, Chair of Toxicology ......................................................................................... 36 2.14 Institute of Pharmacology and Toxicology, Chair of Pharmacology ................................................................................... 38 2.15 Institute of Forensic Medicine .................................................................................................................................... 40 2.16 Institute of Pathology ................................................................................................................................................ 42 2.17 Institute for Medical Radiation and Cell Research ........................................................................................................ 44 2.18 Institute of Human and Medical Genetics .................................................................................................................... 46 2.18.1 Division of Medical Genetics ...................................................................................................................................... 48 3 University Hospital 3.1 Introduction ............................................................................................................................................................. 50 3.2 Department of Anaesthesia and Critical Care ............................................................................................................... 52 3.3 Department of Surgery I ............................................................................................................................................ 54 3.4 Department of Trauma, Hand, Plastic and Reconstructive Surgery ................................................................................. 56 3.5 Institute for Transfusion Medicine and Haemotherapy ................................................................................................... 58 3.6 Department of Thoracic and Cardiovascular Surgery ..................................................................................................... 60 3.7 Department of Urology and Paediatric Urology ............................................................................................................. 62 3.8 Department of Orthopaedics ...................................................................................................................................... 64 3.9 Department of Obstetrics and Gynecology ................................................................................................................... 66 3.10 Department of Pediatrics ........................................................................................................................................... 68 3.11 Department of Internal Medicine I ............................................................................................................................. 70 3.12 Department of Internal Medicine II ............................................................................................................................. 73 3.12.1 Division of Molecular Internal Medicine ....................................................................................................................... 76 3.13 Institute of Clinical Biochemistry and Pathobiochemistry – Central Laboratory (IKBZ) ....................................................... 78 3.14 Department of Dermatology, Venereology and Allergology ............................................................................................. 80 3.15 Institute of Radiology ................................................................................................................................................ 82 3.15.1 Division of Neuroradiology ......................................................................................................................................... 84 3.16 Department of Nuclear Medicine ................................................................................................................................ 86 3.17 Department of Radiation Oncology ............................................................................................................................. 88 3.18 Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery ................................ 90 3.19 Department of Ophthalmology ................................................................................................................................... 92 3.20 Department of Neurosurgery and Division of Pediatric Neurosurgery (until October 2007) ................................................ 94 3.21 Department of Neurology .......................................................................................................................................... 96 3.22 Institute for Clinical Neurobiology ............................................................................................................................... 98 3.23 Department of Psychiatry, Psychosomatics and Psychotherapy with Division of Forensic Psychiatry ................................ 100 3.24 Department for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy .................................................... 102 4 Dental Hospital 4.1 Introduction ........................................................................................................................................................... 105 2 4.2 Department of Orthodontics .................................................................................................................................... 106 4.3 Department of Functional Materials in Medicine and Dentistry .................................................................................... 108 4.4 Department of Oral and Maxillofacial Plastic Surgery .................................................................................................. 110 4.5 Department of Prosthodontics ................................................................................................................................. 112 4.6 Department of Conservative Dentistry and Periodontology ........................................................................................... 114 4.6.1. Division of Periodontology ........................................................................................................................................ 116 5 Additional Scientific Units 5.1 Collaborative Research Centers ...............................................................................................................................
Load more

Recommended publications
  • SFB 1074 Renewal Application PI Profiles 2016-2020
    General Information Name: Prof. Dr. med. Klaus-Michael Debatin Date of Birth: 06.12.1952 Gender: Male Address: Department of Pediatrics and Adolescent Medicine, Ulm University, Eythstrasse 24, 89075 Ulm/Germany Phone: +49 731 500 57001 E-Mail: [email protected] Current Positions: Chairman, Department of Pediatrics, Ulm University Medical Director, University Children’s Hospital Ulm Deputy Coordinating Investigator, Collaborative Research Center (SFB) 1074 “Experimental models and clinical translation in leukemia” Academic Education 1971 - 1978 Medical School, Universities of Ulm, Freiburg and Heidelberg Academic Degrees 1997 Professor of Pediatrics, Ulm University 1990 Habilitation in Pediatrics, University of Heidelberg 1979 Doctorate degree (Dr. med.), University of Heidelberg Professional Experience 2013-2015 CEO and Medical Director, University Medical Center Ulm 2010-2013 Deputy Medical Director, University Medical Center Ulm 2010-2014 Vice President Medicine, Ulm University 2004-2010 Dean, Medical Faculty, Ulm University 2003-2005 Chairman, Science Committee of the Medical Faculty, Ulm University 2002-2004 Vice Dean, Medical Faculty, Ulm University 1995-2002 Head, Division of Molecular Oncology, German Cancer Research Center 1997 Visiting Professor, St. Jude Children’s Research Hospital, Memphis Since 1997 Chairman, Department of Pediatrics, Ulm University Physician-in-chief of the University Children’s Hospital Ulm 1994-1997 Head, Hematology/Oncology Section, University Children's Hospital, Heidelberg 1990-1994
    [Show full text]
  • HY Asiakirjapohja
    BOARD MEETING 3/2013 E-MAIL MEETING 30 September 2013 MINUTES INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine Title: Meeting of the Board of FIMM 3/2013 Time: Monday, 30 September 2013 Place: E-mail Meeting Chair: Vice Rector, Professor Kimmo Kontula, University of Helsinki Attendees: Dean, Professor Risto Renkonen, Faculty of Medicine, University of Helsinki Research Director, Professor Anna-Elina Lehesjoki, Neuroscience Center, University of Helsinki Professor Kimmo Porkka, Institute of Clinical Medicine, Faculty of Medicine, University of Helsinki Chief Research Officer, Professor Lasse Viinikka, HUS Deputy Director General, Professor Juhani Eskola, THL Vice President, Professor, R&D Biotechnology Anu Kaukovirta-Norja, VTT CEO Pekka Mattila, Desentum Oy Director, Professor Eero Vuorio, Biocenter Finland Head of Laboratory Pekka Ellonen, FIMM Technology Centre Presenter: Director, Professor Olli Kallioniemi, FIMM Secretary: Administrative Manager Reetta Niemelä, FIMM 2(5) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine Meeting of the Board of FIMM 3/2013 1 Appointment of the Evaluation Committee for the evaluation of suggested collaboration be- tween FIMM/University of Helsinki and VTT in the field of metabolomics (presenter: Kallioniemi) 2 Dates of the next meetings 3(5) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine 1 Appointment of the Evaluation Committee for the evaluation of suggested collaboration between FIMM/University of Helsinki and VTT in the field of metabolomics (presenter: Kallioniemi) The Directorship of VTT and the University of Helsinki discussed the possible collaboration between FIMM/University of Helsinki and VTT in the field of metabolomics in May 2013.
    [Show full text]
  • Chemotherapy for Breast Cancer
    INFORMATION AND ADVICE Austria CHEMOTHERAPY Brustkrebs Deutschland e. V. Österreichische Krebshilfe-Gesellschaft [Breast Cancer Germany, registered association] [Austrian Cancer Aid Association] FOR BREAST CANCER – Lise-Meitner-Str. 7 Tuchlauben 19 HOW DO I DEAL 85662 Hohenbrunn (district of Munich) AT-1010 Vienna Tel.: +49 (0) 89 / 41 61 98 00 Tel.: +43 (0) 1 / 796 64 50 WITH SIDE EFFECTS? Fax: +49 (0) 89 / 41 61 98 01 Fax: +43 (0) 1 / 796 64 50-9 Free hotline: 0800 0 117 112 www.krebshilfe.net E-Mail: [email protected] DE-HAL-18-00041 (V2.0): 12/2020; HAL0129B www.brustkrebsdeutschland.de Switzerland Deutsche Krebsgesellschaft e. V. [German Cancer Association, registered association] Krebsliga Schweiz Kuno-Fischer-Str. 8 [Cancer League Switzerland] 14057 Berlin Effingerstrasse 40 Tel: + 49 (0) 30 322932-90 CH-3001 Bern Fax: + 49 (0) 30 3229329-22 Tel.: +41 (0) 31 389 91 00 www.krebsgesellschaft.de Fax: +41 (0) 31 389 91 60 [email protected] Krebsinformationsdienst Deutsches Krebsforschungszentrum Cancer telephone and helpline [Cancer Information Service Free hotline: +41 (0) 800 11 88 11 German Cancer Research Centre] E-mail: [email protected] Im Neuenheimer Feld 280 Forum: www.krebsforum.ch 69120 Heidelberg Free hotline: +49 (0) 800 / 420 30 40 www.krebsinformationsdienst.de Stiftung Deutsche Krebshilfe-Infonetz Krebs [German Cancer Aid Foundation-Cancer Information Network] Buschstr. 32 53113 Bonn Tel.: +49 (0) 800 / 80 70 88 77 (free of charge) Mon. to Fri. 8.00 – 17.00 www.infonetz-krebs.de Distribution in Germany: Distribution in Austria: Distribution in Switzerland: Englisch Eisai GmbH Eisai GesmbH, Saturn Tower Eisai Pharma AG Edmund-Rumpler-Straße 3 Leonard-Bernstein-Straße 10 Leutschenbachstrasse 95 60549 Frankfurt am Main A-1220 Vienna CH-8050 Zurich [email protected] [email protected] Tel.: +41 (0) 44 / 306 12 12 INTRODUCTION HELP WITH SELF-HELP Palliative chemotherapy: Therapy with cytostatics aimed at prolonging survival time and improving quality of life.
    [Show full text]
  • EMBL in Finland
    EMBL in Finland Friday 5 October 2018 Biomedicum 1, Lecture Hall 1 Helsinki PROGRAMME 10:00-10:30 Arrival, coffee and registration 10:30-10:40 Welcome remarks 10:30 Marja Makarow, Director, Biocenter Finland, Helsinki (EMBL Heidelberg, Postdoc, 1981-1983; EMBL Council Advisor, 1999-2008; and President of EMBC, 2004-2007) 10:35 Johanna Myllyharju, Scientific Director, Biocenter Oulu and Professor, University of Oulu (EMBL Council Member, 2016-Present) 10:40-12:20 Session 1: EMBL and EMBO opportunities and resources Chair: Johanna Myllyharju, Scientific Director, Biocenter Oulu and Professor, University of Oulu (EMBL Council Member, 2016-Present) 10:40 Rainer Pepperkok, Head of Core Facilities, Head of Advanced Light Microscopy Core Facility, Team Leader and Senior Scientist, EMBL, Heidelberg “EMBL opportunities and resources” 11:20 Kai Simons, Chief Executive Officer, Lipotype, Dresden “EMBL and me” (EMBL Heidelberg, Head of Cell Biology and Biophysics Unit, 1975-2000; and EMBO Council Member, 2004-2009) 11:40 Tomi Määtä, Predoc, EMBL, Heidelberg “My life as a predoc at EMBL” 11:50 Howy Jacobs, Professor of Molecular Biology, University of Tampere “What you can do for EMBO and EMBO can do for you” 12:10 Discussion 12:20-13:20 Lunch and discussion with the speakers PROGRAMME (continued) 13:20-14:30 Session 2: Collaboration opportunities and research infrastructures Panel chair: Merja Särkioja, Senior Science Adviser, Academy of Finland, Helsinki 13:20 Riitta Maijala, Vice President for Research, Academy of Finland, Helsinki “Finland’s strategy
    [Show full text]
  • ADP-Ribosylation with Clostridium Perfringens Iota Toxin
    Biochem. J. (1990) 266, 335-339 (Printed in Great Britain) 335 Inhibition of cytochalasin D-stimulated G-actin ATPase by ADP-ribosylation with Clostridium perfringens iota toxin Udo GEIPEL, Ingo JUST and Klaus AKTORIES* Rudolf-Buchheim-Institut fur Pharmakologie der Universitat GieBen, Frankfurterstr. 107, D-6300 GieBen, Federal Republic of Germany Clostridium perfringens iota toxin belongs to a novel family of actin-ADP-ribosylating toxins. The effects of ADP-ribosylation of skeletal muscle actin by Clostridium perfringens iota toxin on cytochalasin D- stimulated actin ATPase activity was studied. Cytochalasin D stimulated actin-catalysed ATP hydrolysis maximally by about 30-fold. ADP-ribosylation of actin completely inhibited cytochalasin D-stimulated ATP hydrolysis. Inhibition of ATPase activity occurred at actin concentrations below the critical concentration (0.1 /iM), at low concentrations of Mg2" (50 ItM) and even in the actin-DNAase I complex, indicating that ADP-ribosylation of actin blocks the ATPase activity of monomeric actin and -that the inhibitory effect is not due to inhibition of the polymerization of actin. INTRODUCTION perfringens type E strain CN5063, which was kindly donated by Dr. S. Thorley (Wellcome Biotech, Various bacterial ADP-ribosylating toxins modify Beckenham, Kent, U.K.) essentially according to the pro- regulatory GTP-binding proteins, thereby affecting cedure described (Stiles & Wilkens, 1986). Cytochalasin eukaryotic cell function. Pertussis toxin and cholera D was obtained from Sigma (Deisenhofen, Germany). toxin ADP-ribosylate GTP-binding proteins involved in DNAase I was a gift from Dr. H. G. Mannherz transmembrane signal transduction (for a review, see (Marburg, Germany). [oc-32P]ATP, [y-32P]ATP and Pfeuffer & Helmreich, 1988).
    [Show full text]
  • 161104 Press Release Robert Koch Gold Medal 2016 to Kai Simons EN
    PRESS RELEASE Robert Koch Gold Medal 2016 to Kai Simons Berlin/Dresden, 4 November 2016: Kai Simons, founding director of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) and managing director of Lipotype GmbH, receives the Robert Koch Medal in Gold for his lifetime achievements, in particular for his characterization of membrane-forming lipids and the development of the lipid raft concept. The Award Ceremony takes place on Friday, November 4th 2016 at the Berlin-Brandenburg Academy of Sciences and Humanities. Simons has spent his life studying cell membranes, wafer-thin bilayers of fat molecules (“lipids”) that surround each cell of the human body and most cellular compartments. Kai Simons discovered floating nano-assemblies of lipids and proteins in the lipid bilayer of cell membranes that reminded him of the log rafts which Finnish lumberjacks used as platforms drifting downstream – hence the name “lipid rafts”. Simons demonstrated the fascinating properties of these rafts: They are fluid and dynamic, they can appear and disappear. Lipid rafts do not only play a significant role as functional platforms in signal transduction and many other membrane processes, but they are also involved in many diseases such as Alzheimer’s disease and AIDS. “I am overwhelmed!” says laureate Kai Simons. “This award is inspiring and I hope that lipids and lipidomics will continue to stimulate molecular life science research, but ultimately also help to improve health and clinical performance”. Kai Simons started the Cell Biology Program at the European Molecular Biology Laboratory (EMBL) in Heidelberg and moved to Dresden in 2001 to build up the Max Planck Institute of Molecular Cell Biology and Genetics.
    [Show full text]
  • CURRICULUM VITAE KAI SIMONS Name
    CURRICULUM VITAE KAI SIMONS Name Simons First Name Kai Date of birth May 24, 1938 Born in Helsinki, Finland Nationality Finnish Civil status married to Carola Simons born Smeds, three children Address: Max-Planck-Institute of Molecular Cell Biology and Genetics Pfotenhauerstr. 108, 01307 Dresden Telephone +49 351 210 2800 Fax +49 351 210 2900 e-mail [email protected] Education 1964 MD, University of Helsinki Research Positions 1965 - 1967 Postdoctoral Research fellow at the Rockefeller University in New York (Prof. A.G. Bearn) 1967 - 1975 Investigator at the Finnish Medical Research Council, University of Helsinki 1971 - 1972 Acting Professor of Biochemistry, Medical Faculty, University of Helsinki 1976 - 1979 Professor, Department of Biochemistry, University of Helsinki 1975 - 2000 Group Leader at the European Molecular Biology Laboratory, Heidelberg 1982 - 1998 Coordinator of the Cell Biology Programme, at the European Molecular Biology Laboratory, Heidelberg 1998 - 2006 Director of the Max-Planck-Institute of Molecular Cell Biology and Genetics, Dresden Present position 1998 – present Group leader at the Max-Planck-Institute of Molecular Cell Biology and Genetics, Dresden Membership in Societies 1975 European Molecular Biology Organisation 1978 Societas Scientarium Fennica 1987 Heidelberg Academy of Sciences 1996 American Academy of Art and Science 1997 Academia Europaea 1997 Foreign Member of the National Academy of Sciences, USA 1998 German Academy of Sciences Leopoldina 2006- Member/Fellow of ScanBalt Academy Honors 1975 Federation
    [Show full text]
  • Lukas A. Huber Biographical Sketch I Studied Medicine at the University
    Lukas A. Huber Biographical sketch I studied medicine at the University of Innsbruck. I joined the laboratory of Kai Simons at EMBL in Heidelberg (Germany) as postdoc in epithelial biology until 1994. I then moved to the University of Geneva (Switzerland) and worked in the laboratory of Jean Gruenberg on endocytosis in epithelial cells. In 1996 I started my own laboratory at the I.M.P. in Vienna (Austria) and in 2002 I got appointed as professor and head of the Division of Cell Biology and in 2005 as scientific director of the Biocenter of Innsbruck Medical University (Austria). My research interests have expanded to understanding the spatial and temporal resolution of signaling mechanisms in mammalian cells applying molecular cell biology, mouse genetics and functional proteomics. I initiated and coordinated the FP6 EU program GROWTHSTOP, the Austrian Proteomics Platform of the Austrian Genome Program (GEN-AU), a special research program in Innsbruck entitled “Cell proliferation and Cell Death in Tumors” – SFB021 of the Austrian Science Fund (FWF) and actively participate in several EU programs and also coordinate programs. Since 2009 I am also CSO of the ONCOTYROL center of personalized cancer medicine in Innsbruck, Austria and since 2012 founder and scientific director of the Austrian Drug Screening Institute (ADSI). Curriculum vitae Biozentrum der Medizinischen Universität Innsbruck Sektion für Zellbiologie Innrain 80-82 A-6020 Innsbruck Austria Tel: +43-512-9003-70170 Web: http://biocenter.i-med.ac.at/ http://www.oncotyrol.at/ http://www.adsi.ac.at/ Email [email protected] Date of birth 4 July 1961 Place of birth Vienna, Austria Citizenship Austrian Education 1980 Matura, Humanistisches Gymnasium Paulinum, Schwaz, Austria 1989 MD, Medical School, University of Innsbruck, Austria Career History 1987-1989 M.D.
    [Show full text]
  • Closer to Europe — Tremendous Opportunities Close By: Germany Is Applying Interview – a Conversation with Bfarm Executive Director Prof
    CLOSER TO EUROPE The new home of the European Medicines U E Agency (EMA) should be located centrally . E within Europe. Optimally accessible. P Set within a strong neigh bourhood. O R Germany is applying for the city of Bonn, U E at the heart of the European - O T Rhine Region, to be the location - R E of the EMA’s new home. S LO .C › WWW FOREWORD e — Federal Min öh iste Gr r o nn f H a e rm al e th CLOSER H TO EUROPE The German application is for a very European location: he EU 27 will encounter policy challenges Healthcare Products Regulatory Agency. The Institute Bonn. A city in the heart of Europe. Extremely close due to Brexit, in healthcare as in other ar- for Quality and Efficiency in Health Care located in T eas. A new site for the European Medicines nearby Cologne is Europe’s leading institution for ev- to Belgium, the Netherlands, France and Luxembourg. Agency (EMA) must be found. Within the idence-based drug evaluation. The Paul Ehrlich Insti- Situated within the tri-state nexus of North Rhine- EU, the organisation has become the primary centre for tute, which has 800 staff members and is located a mere drug safety – and therefore patient safety. hour and a half away from Bonn, contributes specific, Westphalia, Hesse and Rhineland-Palatinate. This is internationally acclaimed expertise on approvals and where the idea of a European Rhine Region has come to The EMA depends on close cooperation with nation- batch testing of biomedical pharmaceuticals and in re- life.
    [Show full text]
  • The Prevention, Detection and Treatment of Cancer Are Preeminent Goals in Health Policy
    No. 14 April 2, 2014 (Koh) 50 years of research for life without cancer "The prevention, detection and treatment of cancer are preeminent goals in health policy. The DKFZ is the flagship of cancer research in Germany. It has brought forward the development of new approaches in the prevention, diagnosis and treatment of cancer. The DKFZ is an institution that, ever since its inception, has promoted creativity and helped innovative ideas flourish. I congratulate the DKFZ with all its employees on these accomplishments." These were the opening words of the Federal Minister of Education and Research, Prof. Dr. Johanna Wanka, in her welcome address at a press conference held in Berlin on the occasion of the 50th anniversary of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). "The German Cancer Research Center (DKFZ), founded in 1964 in Heidelberg as a national research institute, has seen astonishing changes over those 50 years and has evolved into an internationally renowned center of high-end research," said Otmar Wiestler, Chairman of the Management Board and Scientific Director of DKFZ. From the very beginning, the Center, which was initially not linked to clinics, has had a double mission: to conduct research on the basic biological mechanisms of cancer and translate the results of its research into enhanced methods for the prevention, diagnosis and treatment of cancer. While the initial years were clearly focused on basic research, the DKFZ has gone on to achieve amazing accomplishments in the translation of its research findings into clinical applications. A crucial factor that has facilitated this development was the foundation of the National Center for Tumor Diseases (NCT) Heidelberg in collaboration with Heidelberg University Hospitals and German Cancer Aid (Deutsche Krebshilfe).
    [Show full text]
  • Impact of Bacterial Toxins in the Lungs
    toxins Review Impact of Bacterial Toxins in the Lungs 1,2,3, , 4,5, 3 2 Rudolf Lucas * y, Yalda Hadizamani y, Joyce Gonzales , Boris Gorshkov , Thomas Bodmer 6, Yves Berthiaume 7, Ueli Moehrlen 8, Hartmut Lode 9, Hanno Huwer 10, Martina Hudel 11, Mobarak Abu Mraheil 11, Haroldo Alfredo Flores Toque 1,2, 11 4,5,12,13, , Trinad Chakraborty and Jürg Hamacher * y 1 Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; hfl[email protected] 2 Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; [email protected] 3 Department of Medicine and Division of Pulmonary Critical Care Medicine, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; [email protected] 4 Lungen-und Atmungsstiftung, Bern, 3012 Bern, Switzerland; [email protected] 5 Pneumology, Clinic for General Internal Medicine, Lindenhofspital Bern, 3012 Bern, Switzerland 6 Labormedizinisches Zentrum Dr. Risch, Waldeggstr. 37 CH-3097 Liebefeld, Switzerland; [email protected] 7 Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; [email protected] 8 Pediatric Surgery, University Children’s Hospital, Zürich, Steinwiesstrasse 75, CH-8032 Zürch, Switzerland; [email protected] 9 Insitut für klinische Pharmakologie, Charité, Universitätsklinikum Berlin, Reichsstrasse 2, D-14052 Berlin, Germany; [email protected] 10 Department of Cardiothoracic Surgery, Voelklingen Heart Center, 66333
    [Show full text]
  • Lipid Function in Health and Disease 27 – 30 September 2019 | Dresden, Germany
    Lipid function in health and disease 27 – 30 September 2019 | Dresden, Germany ORGANIZER SPEAKERS Kai Simons Alan Bridge Jens Brüning Robin Klemm Max Planck Institute of Molecular Cell Swiss Insitute of Bioinformatics Max Planck Institute for University of Zurich, CH Biology and Genetics, DE Metabolism Research, DE Allan Tall Rose Goodchild Columbia University College of Jodi Nunnari VIB-KU Leuven Center for Brain & CO-ORGANIZERS Physicians & Surgeons, US University of California, US Disease Research, BE Triantafyllos Chavakis Andrej Shevchenko Kai Simons Rosemary Cornell University Hospital Dresden, DE Max Planck Institute of Molecular Max Planck Institute of Molecular Simon Fraser University, US Cell Biology and Genetics, DE Cell Biology and Genetics, DE Ünal Coskun Samuli Ripatti Paul Langerhans Institute Dresden Arun Radhakrishnan Karin Reinisch Institute for Molecular Medicine, /Helmholtz Zentrum München, DE University of Texas, US Yale School of Medicine, US FI Elina Ikonen Bruno Antonny Mihai Netea Shamshad Cockcroft University of Helsinki, FI Institute of Molecular and Cellular Radboud Universität, NL University College London, UK Pharmacology, FR Mikael Simons Suzanne Pfeffer REGISTRATION Doris Höglinger Technical University Munich, DE Stanford University, US Heidelberg Univeristy, DE Registration deadline Naomi Taylor Theodore Alexandrov 31 May 2019 Edda Klipp NIH National Cancer Institute, US EMBL, DE Humboldt-Universität zu Berlin, DE Nicola Zamboni Triantafyllos Chavakis Student/postdoc ............ 300 EUR ETH Zurich, CH
    [Show full text]